8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 14, 2007
Electro-Optical Sciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51481
|
|
13-3986004 |
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer |
of incorporation)
|
|
File Number)
|
|
Identification No.) |
|
|
|
3 West Main Street, Suite 201, |
|
|
Irvington, New York
|
|
10533 |
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code (914) 591-3783
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 8.01 Other Events
On June 14, 2007, the Registrant issued a press release providing an update on the development of
the Registrants MelaFind® product at the Needham & Co. Biotechnology and Medical
Technology Conference in New York. A copy of the press release is furnished as Exhibit 99.1 to
this report. Exhibit 99.1 is furnished to, but not filed with, the Securities and Exchange
Commission. Registration statements or other documents filed with the Securities and Exchange
Commission shall not incorporate this information by reference, except as otherwise expressly
stated in such filing.
Item 9.01 Financial Statements and Exhibits
(b) Exhibits.
|
|
|
Exhibit |
|
|
Number |
|
Description |
99.1
|
|
Press Release of the Registrant dated June 14, 2007 providing MelaFind® development update |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Electro-Optical Sciences, Inc.
|
|
Date: June 14, 2007 |
By: |
/s/ Joseph V. Gulfo
|
|
|
|
President & Chief Executive Officer |
|
|
|
(Principal Executive Officer) |
|
|
2
EXHIBIT INDEX
|
|
|
EXHIBIT NO. |
|
DESCRIPTION |
99.1
|
|
Press Release of the Registrant dated June 14, 2007 providing MelaFind® development update |
3
EX-99.1
Exhibit 99.1
For further information contact:
David Carey
Lazar Partners Ltd.
(646) 239-6231
dcarey@lazarpartners.com
Electro-Optical Sciences Provides Melafind®
Development Update
IRVINGTON, NY, June 14, 2007 Electro-Optical Sciences, Inc. (EOS) (NASDAQ: MELA), today
provided an update on the development of MelaFind®, a non-invasive, point-of-care
instrument to assist in the early diagnosis of melanoma, at the Needham & Co. Biotechnology and
Medical Technology Conference in New York.
Joseph V. Gulfo, MD, MBA, President & CEO of EOS announced that accrual in the final blinded
pivotal trial of MelaFind is over 20 percent complete. Four pivotal study sites are active, and
additional pivotal trial sites will be activated in the upcoming weeks.
We are very pleased with the operation of the MelaFind systems in the pivotal clinical trial,
which validates the manufacturing development effort we have undertaken over the past 18 months,
Gulfo said. We expect additional clinical trial sites to come online soon and anticipate accrual
to proceed well toward our goal of completing the study in the second half of 2007.
Dr. Gulfo also announced the companys intention to initiate discussions with potential
commercialization partners. This is an appropriate time for us to begin proactive partnering
discussions in anticipation of a potential mid-2008 MelaFind launch, subject to U.S. regulatory
clearance, having demonstrable progress in the execution of the pivotal trial and a solid
manufacturing capability to support commercial roll-out.
About Electro-Optical Sciences
EOS is a medical device company focused on designing and developing a non-invasive, point-of-care
instrument to assist in the early diagnosis of melanoma. MelaFind(R), EOSs flagship product,
features a hand-held imaging device that
emits light of multiple wavelengths to capture images of
suspicious pigmented skin lesions and extract data. Using sophisticated algorithms, the data are
then analyzed against a proprietary database of melanomas and benign lesions in
order to provide information to the physician and produce a recommendation of whether the lesion
should be biopsied.
Melanoma is the deadliest of skin cancers, responsible for approximately 80% of all skin cancer
deaths. Unless melanoma is detected early and excised with proper margins, the patient survival
rate is poor, as there is currently no cure for advanced stage melanoma.
For more information on EOS, visit www.eosciences.com.
Safe Harbor
This press release includes forward-looking statements within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not limited to our plans,
objectives, expectations and intentions and other statements that contain words such as expects,
contemplates, anticipates, plans, intends, believes and variations of such words or
similar expressions that predict or indicate future events or trends, or that do not relate to
historical matters. These statements are based on our current beliefs or expectations and are
inherently subject to significant uncertainties and changes in circumstances, many of which are
beyond our control. There can be no assurance that our beliefs or expectations will be achieved.
Actual results may differ materially from our beliefs or expectations due to economic, business,
competitive, market and regulatory factors.
# # #
2